Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
Immune checkpoint blockade using anti-PD-1 monoclonal antibodies has shown considerable promise in the treatment of solid tumors, but brain tumors remain notoriously refractory to treatment.